MS
Therapeutic Areas
Pharming Group Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Leniolisib (Joenja) | Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) | Approved/Commercial |
| Leniolisib | Other Primary Immunodeficiencies (PIDs) with immune dysregulation | Not Specified |
| Undisclosed Program | Primary Mitochondrial Diseases | Pivotal Stage |
Leadership Team at Pharming Group
FC
Fabrice Chouraqui
Chief Executive Officer & Executive Director
KL
Kenneth Lynard
Chief Financial Officer
AR
Anurag Relan
Chief Medical Officer
LM
Leverne Marsh
Chief Commercial Officer
RV
Ruud van Outersterp
Chief Legal & Compliance Officer
DA
Dr. Alexander Breidenbach
Chief Business Officer
IB
Inés Bernal
Chief People Officer
MR
Maryana Reurings-Tsiganko
Vice President, Strategy & Operations
RP
Richard Peters
Chairman of the Board of Directors
MP
Mark Pykett
Non-Executive Director, Vice-Chair